EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Xavier Leleu iD, Cyrille Hulin, Jerome Lambert, Arthur Bobin, Aurore Perrot iD, Lionel Karlin, Murielle Roussel, Lydia Montes, Brieuc Cherel, Thomas Chalopin, Borhane Slama, Marie-Lorraine Chretien und 48 weitere

Nature Medicine · 2024-08 · 30 (8) · 2235-2241

DOI: 10.1038/s41591-024-03050-2 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nature Medicine, online erschienen am 03.06.2024. Verfasst von Xavier Leleu und 59 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, CIC 1082, U1313, CHU, University, Poitiers, France. xavier.leleu@chu-poitiers.fr. Hauptthemen laut MEDLINE: Multiple Myeloma, Bortezomib, Lenalidomide, Dexamethasone. Die Arbeit wurde bisher 124-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD38-targeting immunotherapy is approved in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM) that are transplant ineligible (TI) and is considered the best standard of care (SOC). To improve current SOC, we evaluated the added value of weekly bortezomib (V) to isatuximab plus lenalidomide and dexamethasone (IsaRd versus Isa-VRd). This Intergroupe Francophone of Myeloma phase 3 study randomized 270 patients with NDMM that were TI, aged 65–79 years, to IsaRd versus Isa-VRd arms. The primary endpoint was a minimal residual disease (MRD) negativity rate at 10 −5 by next-generation sequencing at 18 months from randomization. Key secondary endpoints included response rates, MRD assessment rates, survival and safety. The 18-month MRD negativity rates at 10 −5 were reported in 35 patients (26%, 95% confidence interval (CI) 19–34) in IsaRd versus 71 (53%, 95% CI 44–61) in Isa-VRd (odds ratio for MRD negativity 3.16, 95% CI 1.89–5.28, P < 0.0001). The MRD benefit was consistent across subgroups at 10 −5 and 10 −6 , and was already observed at month 12. The proportion of patients with complete response or better at 18 months was higher with Isa-VRd (58% versus 33%; P < 0.0001), as was the proportion of MRD negativity and complete response or better (37% versus 17%; P = 0.0003). At a median follow-up of 23.5 months, no difference was observed for survival times (immature data). The addition of weekly bortezomib did not significantly affect the relative dose intensity of IsaRd. Isa-VRd significantly increased MRD endpoints, including the 18-month negativity rate at 10 −5 , the primary endpoint, compared with IsaRd. This study proposes Isa-VRd as a new SOC for patients with NDMM that are TI. ClinicalTrials.gov identifier: NCT04751877 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaBortezomibLenalidomideDexamethasoneAntineoplastic Combined Chemotherapy ProtocolsHumansAgedMaleFemaleAntibodies, Monoclonal, HumanizedNeoplasm, ResidualTreatment Outcome

Substanzen

BortezomibLenalidomideDexamethasoneisatuximabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Hematology, CIC 1082, U1313, CHU, University, Poitiers, France. xavier.leleu@chu-poitiers.fr.
  • CHU, Bordeaux, France.
  • SBIM, Saint-Louis Hospital, Paris, France.
  • Hematology, CIC 1082, U1313, CHU, University, Poitiers, France.
  • University Hospital, iUCT Oncopole, Toulouse, France.
  • Hôpital Lyon Sud, Pierre-Benite, France.

ORCID-Profile: Xavier Leleu, Aurore Perrot, Jill Corre

Förderung

  • NCI NIH HHS
  • Sanofi

Zitieren

APA

Leleu, X., Hulin, C., Lambert, J., Bobin, A., Perrot, A., Karlin, L., Roussel, M., Montes, L., Cherel, B., Chalopin, T., Slama, B., Chretien, M. L., Laribi, K., Dingremont, C., Roul, C., Mariette, C., Rigaudeau, S., Calmettes, C., Dib, M., …, & Corre, J. (2024). Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nature Medicine, 30(8), 2235-2241. https://doi.org/10.1038/s41591-024-03050-2

Vancouver

Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nature Medicine. 2024;30(8):2235-2241. doi:10.1038/s41591-024-03050-2

BibTeX
@article{Leleu2024,
  author = {Leleu, Xavier and Hulin, Cyrille and Lambert, Jerome and Bobin, Arthur and Perrot, Aurore and Karlin, Lionel and Roussel, Murielle and Montes, Lydia and Cherel, Brieuc and Chalopin, Thomas and Slama, Borhane and Chretien, Marie-Lorraine and Laribi, Kamel and Dingremont, Claire and Roul, Christophe and Mariette, Clara and Rigaudeau, Sophie and Calmettes, Claire and Dib, Mamoun and Tiab, Mourad and Vincent, Laure and Delaunay, Jacques and Santagostino, Alberto and Macro, Margaret and Bourgeois, Emmanuelle and Orsini-Piocelle, Frederique and Gay, Julie and Bareau, Benoit and Bigot, Noemie and Vergez, François and Lebreton, Pierre and Tabrizi, Reza and Waultier-Rascalou, Agathe and Frenzel, Laurent and Le Calloch, Ronan and Chalayer, Emilie and Braun, Thorsten and Lachenal, Florence and Corm, Selim and Kennel, Celine and Belkhir, Rakiba and Bladé, Jean-Sebastien and Joly, Bertrand and Richez-Olivier, Valentine and Gardeney, Helene and Demarquette, Helene and Robu-Cretu, Daniela and Garderet, Laurent and Newinger-Porte, Muriel and Kasmi, Amine and Royer, Bruno and Decaux, Olivier and Arnulf, Bertrand and Belhadj, Karim and Touzeau, Cyrille and Mohty, Mohamad and Manier, Salomon and Moreau, Philippe and Avet-Loiseau, Hervé and Corre, Jill},
  title = {Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial},
  journal = {Nature Medicine},
  year = {2024},
  volume = {30},
  number = {8},
  pages = {2235--2241},
  doi = {10.1038/s41591-024-03050-2}
}
Kostenlos starten →